A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19

Fudan University

Status: Enrolling

Conditions: COVID-19

Treatments: Drug: Paxlovid

Study type: Observational

Funder types: Other

Identifiers

NCT05387369

KY2022-552

Details and patient eligibility

About

The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.

Full description

The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who have a positive SARS-CoV-2 test result;
• Participants who have one or more mild or moderate COVID-19 symptoms.

Exclusion criteria

• No specific exclusion criteria in this real world study.

Trial design

2,000 participants in 2 patient groups

Paxlovid

Description:

Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive Paxlovid therapy

Treatment:

Drug: Paxlovid

Routine therapy

Description:

Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive routine therapy without paxlovid